Form 4: Apellis Director Dolsten Receives Equity Grants

Apellis Pharmaceuticals director Mikael Dolsten was granted 14,312 restricted stock units and 24,135 stock options on February 27, 2026, aligning his interests with shareholders.

Summary

• Mikael Dolsten, a Director at Apellis Pharmaceuticals, Inc. (APLS), was granted equity awards on February 27, 2026.
• The awards include 14,312 shares of common stock in the form of Restricted Stock Units (RSUs).
• These RSUs will fully vest on the first anniversary of the grant date, February 27, 2027, contingent on his continued service as a director or upon later termination at his election.
• Additionally, Dolsten received 24,135 stock options with an exercise price of $20.96 per share.
• These stock options will vest in equal one-third increments annually over a three-year period, subject to his continued service. The vesting dates would be February 27, 2027, February 27, 2028, and February 27, 2029.
• The stock options have an expiration date of February 27, 2036.
• Following these transactions, Dolsten beneficially owns 14,312 shares of common stock and 24,135 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued alignment of a key director's interests with shareholders through equity compensation, which is a standard and healthy corporate governance practice.

Positives

• The grant of restricted stock units and stock options aligns the director's financial interests with those of long-term shareholders.
• Equity compensation is a standard practice to attract and retain experienced board members.
• The vesting schedules encourage continued service and commitment to the company's performance over several years.

Future Outlook

The vesting schedules for the restricted stock units and stock options indicate a future commitment from Director Mikael Dolsten, with RSUs fully vesting in one year and stock options vesting over three years, contingent on his continued service.

Industry Context

StockSavvy.ai notes that the granting of equity awards to directors is a common practice across the biotechnology and pharmaceutical industries. This compensation structure is designed to align the interests of board members with those of shareholders, encouraging long-term value creation. Such grants are typical for retaining experienced leadership in a competitive sector.

Comparison to Industry Standards

• StockSavvy.ai observes that the equity compensation package for Director Mikael Dolsten, comprising both restricted stock units and stock options with multi-year vesting, is consistent with standard practices for non-executive directors in publicly traded biotechnology companies.
• For instance, similar structures are seen at companies like Biogen Inc. or Regeneron Pharmaceuticals, Inc., where director compensation often includes a mix of cash and equity to incentivize long-term performance and retention.
• The specific number of units and options would typically be benchmarked against peer groups based on company size, market capitalization, and industry averages for director compensation.

Corporate Governance

Related Party Transactions

• The grant of 14,312 restricted stock units and 24,135 stock options to Mikael Dolsten, a director of Apellis Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of director's interests with long-term shareholder value.

Next Steps

• Mikael Dolsten's continued service as a director at Apellis Pharmaceuticals, Inc.
• Vesting of 14,312 restricted stock units on February 27, 2027.
• Annual vesting of 24,135 stock options over three years, starting February 27, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice. While it indicates continued insider alignment, it does not present new fundamental information that would significantly alter the investment thesis for Apellis Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Apellis Pharmaceuticals, APLS, Mikael Dolsten, Form 4, SEC filing, insider transaction, restricted stock units, stock options, equity grant, director compensation, corporate governance